AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for RNA-binding protein NOB1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9ULX3

UPID:

NOB1_HUMAN

Alternative names:

Phosphorylation regulatory protein HP-10; Protein ART-4

Alternative UPACC:

Q9ULX3; Q7L6B7; Q7M4M4; Q7Z4B5; Q9NWB0

Background:

RNA-binding protein NOB1, also known as Phosphorylation regulatory protein HP-10 and Protein ART-4, plays a crucial role in cellular processes. It is involved in mRNA degradation and is essential for the processing of 20S pre-rRNA precursor, facilitating the biogenesis of 40S ribosomal subunits. This protein's function underscores its importance in the maintenance and efficiency of the ribosome, the cell's protein factory.

Therapeutic significance:

Understanding the role of RNA-binding protein NOB1 could open doors to potential therapeutic strategies. Its pivotal role in ribosomal biogenesis and mRNA degradation pathways highlights its potential as a target for interventions in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.